| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Royalty Pharma plc$58.42
+1.13 (+1.96%)
C 46Pipeline Score NOT_PHARMA · Commercial
Market Cap
31.39 B
EPS
1.91
P/E Ratio
28.54 $
Value Trade
245.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
630.58 M
R&D Expenses
39.79 M
Operating CF
718.23 M
Total Assets
19.82 B
Total Liabilities
9.88 B
Equity
9.94 B
D/E Ratio
12,345
4.01 %
Week
10.15 %
1 Month
21.43 %
3 Month
41.3 %
6 Month
34.7 %
5 Year
23.86 %
All Time
Cash Data
Cash Position
608.29 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
3.72 M
52 Week Range
32.21 - 54.64
% held by Insiders
6.37 %
% held by Institutions
83.75 %
Enterprise Value
42.78 B
Total Shares
443.41 M
Short %
3 %
Float Shares
435.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Royalty Pharma plc
135Total events
3Upcoming
86Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T1NDA Submission
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-26 | Aficamten | PDUFA Date | PDUFA | Approved | – | – | – |
2025-12-26 | Aficamten | PDUFA Date | PDUFA | Approved | – | – | – |
2025-12-26 | Aficamten | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
C46
Pipeline Score $1.3B
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 71%
Mid Cap (rank 266 of 913)
Percentile RankRoyalty Pharma plc carries a moderate pipeline score (46/100), with $3.1B risk-adjusted pipeline value, led by valacyclovir in HIV Infections (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| valacyclovir Small molecule | HIV Infections | Phase 2 | NCT00530777 | 40% | $3.1B | COMPLETED | 148 | - | - | Aug 1, 2010 | - | Dec 19, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RPRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RPRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RPRX▲ +2%today
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma
Neurimmune has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including an upfront payment of $125 million. This deal will provide Neurimmune with non-dilutive funding to support its R&D pipeline. Cliramitug, an investigational monoclonal antibody, aims to address amyloid transthyretin cardiomyopathy (ATTR-CM) and is currently in a Phase 3 trial under AstraZeneca's management.
Read more →RPRXRoyalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 9, 2026. The event will feature a fireside chat at 4:00 p.m. ET, and the webcast will be available on the company's website. Royalty Pharma is recognized for its significant role in funding biopharmaceutical innovation.
Read more →RPRXRoyalty Pharma to present at upcoming investor conferences
Royalty Pharma plc (Nasdaq: RPRX) will participate in two investor conferences in May 2026. The BofA Securities Healthcare Conference is scheduled for May 13, and the RBC Capital Markets Global Healthcare Conference will take place on May 19. Webcasts of these events will be available on the company's website and archived for thirty days.
Read more →RPRXRoyalty Pharma reports first quarter 2026 results
Royalty Pharma plc reported strong financial results for Q1 2026, with Portfolio Receipts increasing by 10% to $925 million and Royalty Receipts growing by 13%. The company raised its full-year guidance for Portfolio Receipts, anticipating between $3,325 million and $3,450 million. Key developments include successful R&D collaborations and positive clinical outcomes for products in its portfolio.
Read more →RPRXHENRY FERNANDEZ STEPS DOWN FROM ROYALTY PHARMA S
Henry Fernandez has stepped down as Lead Independent Director of Royalty Pharma, effective August 13, 2025. He joined the Board in July 2020 and has played a crucial role in the company's growth since its IPO. The CEO praised his contributions, stating that Fernandez's leadership helped achieve significant milestones. The company plans to appoint a new Lead Independent Director soon.
Read more →RPRXROYALTY PHARMA REPORTS SECOND QUARTER 2025 RESULTS Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised full year 2025 guidance
Royalty Pharma plc reported strong financial results for Q2 2025, achieving a 20% increase in Portfolio Receipts, reaching $727 million. The firm raised its full-year guidance and completed a strategic acquisition of its external manager, marking its transition to an integrated company. A notable funding agreement with Revolution Medicines further supports its growth strategy. However, operating cash flow dropped significantly, and a legal dispute over royalties with Vertex raises concerns about future revenue stability.
Read more →RPRXROYALTY PHARMA APPOINTS CAROLE HO AND ELIZABETH WEATHERMAN TO THE COMPANY S BOARD OF DIRECTORS Strengthens Board of Directors with appointment of two new independent members, increasing independent represen
Royalty Pharma announced the appointments of Carole Ho and Elizabeth Weatherman to its Board of Directors. Ho brings extensive experience in therapeutic development at Denali Therapeutics, while Weatherman has a solid background in healthcare investing with Warburg Pincus. These additions are expected to bolster the board's capabilities and support Royalty Pharma's long-term strategy. The company aims to strengthen its position as a leader in biopharmaceutical royalties.
Read more →RPRXROYALTY PHARMA REPORTS FIRST QUARTER 2025 RESULTS Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12% Net cash provided by operating activities of $596 million Raised full year 2025 guidance:
Royalty Pharma plc (Nasdaq: RPRX) reported robust financial results for Q1 2025, showcasing a 17% increase in Portfolio Receipts to $839 million and a 12% rise in Royalty Receipts. The company also raised its full-year guidance, driven by strong performances across various therapeutic franchises. A significant share repurchase program and an R&D partnership with Biogen highlight Royalty Pharma's strategic initiatives. However, net cash from operating activities saw a decline from the previous quarter, raising some concerns regarding short-term cash flows.
Read more →RPRXROYALTY PHARMA APPOINTS VLAD CORIC, M.D. TO THE COMPANY S
Royalty Pharma has appointed Vlad Coric, M.D. to its Board of Directors, effective immediately. Coric is recognized for his successful tenure as Chairman and CEO of Biohaven, where he led the development of significant migraine treatments. His extensive experience in drug discovery and clinical development, along with a strong leadership background, is anticipated to strengthen Royalty Pharma's capabilities in funding innovations within the biopharmaceutical sector.
Read more →RPRXROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2024 RESULTS Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024 Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operati
Royalty Pharma plc (Nasdaq: RPRX) reported strong Q4 and full year 2024 results, with Royalty Receipts growing by 12% year-over-year. The company successfully deployed $2.8 billion in capital and introduced a new $3 billion share repurchase program. Despite a decrease in Portfolio Receipts by 8% for the full year compared to 2023, the company anticipates continued growth with new product launches and the acquisition of its external manager expected to improve economic returns. Overall, Royalty Pharma remains optimistic about its position and future opportunities.
Read more →RPRXJ.P. Morgan Healthcare Conference January 2025 2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an of
Royalty Pharma plc presented at the J.P. Morgan Healthcare Conference with a focus on their forward-looking strategies and financial performance. They projected 2024 portfolio receipts to reach approximately $2.8 billion, which is at the high end of previous guidance. Furthermore, the company announced a new $3 billion share repurchase program and significant expected cash savings from internalizing its management structure, reinforcing its commitment to shareholder value and operational efficiency.
Read more →RPRX▲ +12.6%on this newsshared move
ROYALTY PHARMA ANNOUNCES TRANSFORMATIVE STEP IN COMPANY'S EVOLUTION WITH ACQUISITION OF ITS EXTERNAL MANAGER AND $3 BILLION SHARE REPURCHASE PROGRAM Royalty Pharma plc to become an integrated company by acquiring its ext
Royalty Pharma plc has announced a strategic acquisition of its external manager and a $3 billion share repurchase program, signaling a transformative step in the company's evolution. The internalization of management aims to enhance shareholder alignment and corporate governance while driving long-term value creation. Additionally, the company anticipates substantial cash savings from this internalization amounting to over $1.6 billion over the next decade. This move reflects Royalty Pharma's confidence in its financial outlook and commitment to repurchasing shares at a favorable discount.
Read more →RPRX▲ +12.6%on this newsshared move
ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance r
Royalty Pharma plc (Nasdaq: RPRX) announced a business update in anticipation of the upcoming J.P. Morgan Healthcare Conference. The company projects Portfolio Receipts of about $2.8 billion for 2024, at the upper end of its previous guidance, driven by strong royalty performance. Significant developments include the potential for new royalties from a growing pipeline, including recent FDA approvals for therapies targeting serious conditions. The company has undertaken transformative steps to enhance shareholder value through acquisitions and increased share repurchases.
Read more →RPRXROYALTY PHARMA REPORTS THIRD QUARTER 2024 RESULTS Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15% Net cash provided by operating activities of $704 million Capital Deployment of approxima
Royalty Pharma plc (RPRX) reported strong financial results for Q3 2024, achieving a 15% growth in Portfolio Receipts, totaling $735 million. The company also raised its full-year guidance, reflecting confidence in its ongoing performance. Significant capital deployment, amounting to approximately $1.2 billion, includes royalties on three innovative therapies. Furthermore, recent FDA approvals for Voranigo and Cobenfy highlight the robustness of the company's portfolio.
Read more →RPRXROYALTY PHARMA REPORTS SECOND QUARTER 2024 RESULTS Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $658 million Raising full year 2024 guidanc
Royalty Pharma plc (Nasdaq: RPRX) reported strong financial results for the second quarter of 2024, with a 12% increase in Portfolio Receipts reaching $608 million. The company raised its full-year guidance for 2024, supported by robust capital deployment exceeding $2 billion in investments across several therapies. Performance enhancements stem from favorable clinical updates, while acknowledging ongoing challenges such as regulatory outcomes and competition for some therapies. The firm remains confident in its ability to sustain growth.
Read more →RPRXROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 2024 guidance confirmed: Por
Royalty Pharma plc reported its financial results for the first quarter of 2024, highlighting a 14% growth in Royalty Receipts amounting to $705 million. However, Portfolio Receipts fell by 37% to $717 million, primarily due to a significant base of comparison from the previous year. The company confirmed its full-year guidance and announced the acquisition of royalties on frexalimab, expanding its development-stage portfolio. CEO Pablo Legorreta emphasized the company's capability to generate long-term growth amidst ongoing healthcare innovations.
Read more →RPRXROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upp
Royalty Pharma provided a business update during the 42nd Annual J.P. Morgan Healthcare Conference, highlighting its strong performance and future outlook. The company expects Portfolio Receipts to reach approximately $3.05 billion for 2023, exceeding previous guidance. Notably, Royalty Pharma has seen consistent double-digit growth since its IPO in 2020. The firm has made significant investments in innovative therapies, including recent acquisitions that bolster its diversified portfolio, indicating a positive trajectory in capital deployment and growth in the biopharmaceutical sector.
Read more →RPRXROYALTY PHARMA RAISES FULL YEAR 2023 GUIDANCE Royalty Pharma now expects 2023 Adjusted Cash Receipts (1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions.
Royalty Pharma plc has increased its full year 2023 Adjusted Cash Receipts guidance to between $2,850 million and $2,950 million, following a $475 million milestone payment from Pfizer after the FDA approved Zavzpret, a nasal spray for migraine treatment. This development highlights Royalty Pharma's ability to generate significant revenue from its royalty agreements. The guidance revision reflects the company's positive outlook but is conditioned upon no unforeseen adverse events. The CEO expressed optimism about creating long-term shareholder value through strategic investment of the new funds.
Read more →RPRXROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,
Royalty Pharma plc provided a business update at the 41st Annual J.P. Morgan Healthcare Conference, highlighting key accomplishments for 2022. The company expects to report $2,140 to $2,150 million in net cash from operating activities, and approximately $2,785 to $2,790 million in adjusted cash receipts, indicating a strong growth of 31% year-over-year. The presentation also emphasized significant capital deployment into innovative therapies, with expectations of continued growth driven by a robust royalty portfolio and capital deployment strategy.
Read more →RPRXROYALTY PHARMA AGREES TO ACQUIRE ROYALTY INTEREST IN TRELEGY ELLIPTA FROM THERAVANCE AND INNOVIVA FOR $1.31 BILLION AND POTENTIAL MILESTONES OF $300 MILLION Further diversifies Royalty Pharma s portfolio with market-lead
ROYALTY PHARMA AGREES TO ACQUIRE ROYALTY INTEREST IN TRELEGY ELLIPTA FROM THERAVANCE AND INNOVIVA FOR $1.31 BILLION AND POTENTIAL MILESTONES OF $300 MILLION July 13, 2022 Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELE
Read more →RPRXROYALTY PHARMA INVESTOR DAY HIGHLIGHTS STRONGER GROWTH OUTLOOK AND THE POWER OF ITS UNIQUE BUSINESS MODEL TO DRIVE VALUE FOR ALL STAKEHOLDERS New capital deployment target of $10-12 billion over the next five years Outlo
ROYALTY PHARMA INVESTOR DAY HIGHLIGHTS STRONGER GROWTH OUTLOOK AND THE POWER OF ITS UNIQUE BUSINESS MODEL TO DRIVE VALUE FOR ALL STAKEHOLDERS NEW YORK, NY, May 17, 2022 Royalty Pharma plc (Nasdaq: RPRX) will host its inaugural Investor Day in New York City today. Royalty Pharm
Read more →RPRX▲ +5.4%on this news
ROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2021 Net cash provided by operating activities (GAAP) expected to be in the range of $
ROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE YORK, NY, January 10, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments and
Read more →RPRXROYALTY PHARMA ANNOUNCES $2.025 BILLION STRATEGIC FUNDING PARTNERSHIP WITH MORPHOSYS Royalty Pharma to provide tailored funding solution to enable MorphoSys acquisition of Constellation Pharmaceuticals Investment is anch
ROYALTY PHARMA ANNOUNCES $2.025 BILLION STRATEGIC FUNDING PARTNERSHIP WITH NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE:MOR; Nasdaq:MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoS
Read more →RPRXROYALTY PHARMA REPORTS Q4 2020 AND FULL-YEAR RESULTS Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow (2) $2.4 billion of acquisitions announced in 2020; maintained leading s
ROYALTY PHARMA REPORTS Q4 2020 AND FULL-YEAR RESULTS NEW YORK, NY, February 17, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter of 2020 and introduced full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial me
Read more →RPRXROYALTY PHARMA REPORTS THIRD QUARTER 2020 RESULTS Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts (1) Increased 2020 guidance: Adjusted Cash Receipts (1) expected to be
ROYALTY PHARMA REPORTS THIRD QUARTER 2020 RESULTS NEW YORK, NY (November 10, 2020) - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure)
Read more →RPRXROYALTY PHARMA ANNOUNCES CLOSING OF $6.0
PHARMA ANNOUNCES CLOSING OF $6.0 BILLION SENIOR UNSECURED NOTES YORK, NY - September 2, 2020 - Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the The Note
Read more →RPRXROYALTY PHARMA ANNOUNCES LAUNCH OF SENIOR NOTES OFFERING NEW YORK (NY)
PHARMA ANNOUNCES LAUNCH OF SENIOR NOTES OFFERING YORK (NY) - August 19, 2020 - Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the "Notes") in a private offering exempt from regis
Read more →RPRXROYALTY PHARMA REPORTS SECOND QUARTER 2020 RESULTS Strong double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts (1) (non-GAAP) Company introduces 2020 guidance: Adjusted Cash
ROYALTY PHARMA REPORTS SECOND QUARTER 2020 RESULTS NEW YORK, NY (August 12, 2020) Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2020 and introduced full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure
Read more →RPRXROYALTY PHARMA APPOINTS HENRY A. FERNANDEZ AND TED W. LOVE, M.D. TO THE COMPANY'S BOARD OF DIRECTORS NEW YORK, NY (US)
APPOINTS HENRY A. FERNANDEZ AND TED W. LOVE, M.D. TO THE COMPANY'S BOARD OF DIRECTORS YORK, NY (US), August 3, 2020 - Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective immedi
Read more →RPRXPRE-QUARTERLY RESULTS COMMUNICATION NEW YORK, NY (US)
PRE-QUARTERLY RESULTS (US), July 14, 2020 - Royalty Pharma (NASDAQ: RPRX) intends to announce its financial results for the second quarter of 2020 on August 12, 2020. An invitation for the results webcast will follow shortly. To assist in the financial modelling of its Q2 2020
Read more →Competitive Position
How RPRX ranks across every disease it competes inCompetitive Position is a premium feature
See how RPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial